Search PubMed⌕ Search

Biomedical subjects

B Bureau

Publications and source records attributed to B Bureau.

At least 37 records · Page 2Linked to original sources
PubMed1993

Cutaneous anaplastic T-cell lymphoma in a patient with human immunodeficiency virus infection: detection of Epstein-Barr virus DNA.

The Epstein-Barr virus (EBV) genome exists in tumour cells of T-cell lymphomas in non-immunosuppressed patients. We identified EBV-DNA by in situ hybridization in a case of anaplastic T-cell lymphoma associated with acquired immunodeficiency syndrome (AIDS). EBV-DNA has been reported in AIDS-related Hodgkin's disease or B-cell lymphoma, but never in T-cell lymphoma. Although our results suggest that EBV could play a role in the development of these anaplastic T-cell lymphomas, the mechanism of EBV penetration into T-cells remains uncertain.

DNA, Viral↗
PubMed1993

In vitro induction of basal keratinocyte MY7 antigen expression in cutaneous T-cell lymphoma is associated with response to interferon-alfa therapy.

BACKGROUND: Normal basal cell keratinocytes express an antigen recognized by monoclonal antibody MY7. This expression is lost in cutaneous T-cell lymphoma (CTCL) and may be reinduced under interferon-alfa-2a therapy. We investigated whether similar modulation of MY7 antigen could be obtained in vitro and determined the relationship between in vitro modulation and clinical response. SUBJECTS: We studied MY7 expression by basal cell keratinocytes in reconstituted skin specimens from 10 patients with CTCL and from skin specimens from five control patients and determined its modulation by interferon-alfa-2a and interleukin 1 using the indirect immunofluorescence technique. Concurrently, clinical examination and in vivo immunologic study on cutaneous biopsy specimens were carried out for these 10 patients before and while receiving interferon-alfa-2a therapy. RESULTS: In vitro studies showed that in five control specimens MY7 expression by basal cells was constant without modulation by interferon-alfa-2a or interleukin 1. Two of 10 CTCL specimens spontaneously expressed MY7 antigen while an additional five did so after incubation with interferon-alfa-2a and the last three never did. CONCLUSION: The three patients with CTCL for whom no MY7 expression was observed in reconstituted skin studies were "poor responders" to interferon-alfa-2a therapy. The five patients with CTCL for whom in vitro MY7 expression was induced by interferon-alfa-2a were responders. For the last two patients, results were variable. Thus, in vitro MY7 antigen is expressed in normal basal cell keratinocytes, absent in CTCL basal cell keratinocytes, but can be induced by interferon-alfa-2a. Moreover this in vitro modulation appears to be possibly correlated with interferon-alfa efficacy in vivo.

Antigens, CD↗
PubMed1993

[Blue rubber bleb nevus].

Blue Rubber Bleb Naevus (BRBN) is characterized by the presence of bluish haemangiomas on the skin and in the digestive tract. We report a new familial case of this rare entity. Analysis of this female patient's pedigree confirmed that BRBN is transmitted as an autosomal dominant trait. In this particular case gastrointestinal haemangiomas appeared over a 4-year period. Although all treatments of this disease have proved disappointing on the skin as well as in the digestive tract, we insist on the need for a regular and prolonged surveillance.

Adult↗
PubMed1993

[Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].

In the treatment of disseminated malignant melanoma (DMM), the results obtained with fotemustine associated or not with dacarbazine are promising and those obtained with interféron alpha are also interesting. Therefore, we have investigated the efficacy and the toxicity of a combined chemotherapy with fotemustine-dacarbazine and interferon alpha in DMM. We present in this work our results on 44 patients who entered into this opened study. 37 patients were evaluable. 29 (78.4 p. 100) had previously received one or more cytotoxic chemotherapy. The regimen consisted of an induction treatment with fotemustine (100 mg/m2) on days 1.8, and 60 dacarbazine (400 mg/m2) on days 1, and 60 and subcutaneous injections of interféron (9.10(6) UI) alpha three times weekly. Responding and stabilized patients were given maintenance treatment with a monthly infusion of fotemustine (100 mg/m2) and dacarbazine (400 mg/m2) and interferon alpha carried on at the same dose. The response rate was 10.8 p. 100 (3 PR + 1 CR). Responses have depended on metastatic sites (cerebral site 18,2 p. 100). The median duration of response was 28 weeks. Toxicity was mainly hematologic and was acceptable. These results are not as good as those reported before with fotemustine and dacarbazine. Even if reasons related to patients and protocol could be discussed, the association of interferon alpha, fotemustine and dacarbazine seems devoid of interest during induction treatment.

Adult↗
PubMed1992

Role of aluminium in skin reactions after diphtheria-tetanus-pertussis-poliomyelitis vaccination: an experimental study in rabbits.

The occurrence of subcutaneous nodules at the injection site is one of the complications of diphtheria-tetanus-pertussis-poliomyelitis vaccination, but the causes and mechanisms involved are still poorly understood. An experimental study in the New Zealand rabbit enabled us to determine the frequency of occurrence of these nodules, how long they persist and the histopathologic features of the cells involved. Aluminium (Al) assays by electrothermal atomic absorption spectrometry allowed us to study concentrations both in nodules and the organism (serum, normal skin). The results show an absence of Al diffusion outside nodules, a correlation between infiltrate intensity and Al concentration in nodules and modifications in the histological constituents of nodule cells. The histological picture indicates a foreign body reaction to Al. All these data underscore the role of Al in the formation of early postvaccinal nodules at the injection site.

Aluminum↗
PubMed1992

Induction of myelo-monocytic My7 antigen (CD13) expression by interferon-alpha in basal cells of cutaneous T-cell lymphomas.

The My7 antigen that is expressed on the basal cells in normal skin and inflammatory disorders is absent in the lesions of cutaneous T-cell lymphoma (CTCL). Induction of My7 expression in basal cells in the cutaneous lesions of 12 patients with mycosis fungoides and three with Sézary syndrome treated with interferon-alpha 2a (IFN-alpha 2a) for 10 months was investigated. Biopsies were taken from the same area before treatment and after 2, 6 and 10 months of therapy with IFN-alpha 2a. My7 antigen was expressed on the basal cells only in those patients who showed either a complete or partial response to therapy with IFN-alpha 2a.

Antigens, CD↗
PubMed1990

MY7 monoclonal antibody for diagnosis of cutaneous T-cell lymphoma.

Infiltrate in cutaneous T-cell lymphomas (CTCLs) is composed mainly of CD4 helper cells with a phenotype very similar to that of benign cutaneous lymphoid infiltrate. MY7 (CD13) is a monoclonal antibody that is normally expressed on peripheral granulocytes and monocytes but also cross-reacts with an antigen expressed on epidermal basal cells. We studied MY7 expression on basal cells of the epidermis and CD4 cell infiltrate in 34 CTCLs, 11 pseudolymphomas, and 29 other benign cutaneous lesions. An indirect immunofluorescence technique with double labeling and an immunoperoxidase technique were used. We found that in benign inflammatory infiltrate, less than 10% of CD4 cells expressed MY7 antigen associated with normal MY7 monoclonal antibody labeling of basal cells, whereas in CTCLs more than 50% of CD4 tumoral cells in dermis expressed MY7 antigens; however, basal cells were MY7 negative. Thus, it is demonstrated that MY7 monoclonal antibody with its double modulation on epidermis (basal cells) and dermis (CD4 cells) has diagnostic value for differentiating CTCLs with CD4+ MY7+ tumor cells in dermis and MY7-negative basal cells from benign inflammatory lesions with CD4+ MY7- cells in dermis and MY7-positive basal cells. This modulation of MY7 labeling could be related to the secretion of epidermal cytokines.

Antibodies, Monoclonal↗
PubMed1988

Immunohistological study of captopril-induced late cutaneous eruptions.

Immunohistological study of dermal infiltrate from two pemphigus- and one captopril-induced lichenoid eruption showed the presence of a CD8 (T suppressor) infiltrate that resembled that found in skin eruptions induced by graft-versus-host disease. It is suggested that a T cell cytotoxic reaction occurs in the epidermis that might be triggered by captopril-induced modification of keratinocytic antigens.

Aged↗
PubMed1986

Cutaneous immunological studies in diagnosis of acute graft-versus-host disease.

A comparative study of the healthy skin of patients who had undergone bone marrow grafting and not developed graft-versus-host disease (GVHD) and of patients with cutaneous lesions of acute GVHD has been carried out. The aim of this study was to assess the diagnostic value of cutaneous immunopathology in the diagnosis of acute GVHD. A double-labelling immunofluorescence technique was used with a panel of monoclonal antibodies. The results showed a lack of specificity for GVHD in the distribution of Langerhans cells, but confirmed the diagnostic value of HLA-DR staining of epidermal keratinocytes. Cellular polymorphism of the T cell infiltrate in the dermis was observed (T helpers 40% and T suppressors 20%). The expression of the 55-57 Kd keratin polypeptide and of bullous pemphigoid antigen showed modification during acute GVHD while that of pemphigus antigen remained unchanged.

Acute Disease↗